FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01.56	ecuo	n 30(n) c	n the i	nvesum	ent Co	ompany Act of	1940								
	ame and Address of Reporting Person* W INVESTMENTS, LP					2. Issuer Name and Ticker or Trading Symbol Milestone Pharmaceuticals Inc. [MIST]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) (First) (Middle) 40 10TH AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 03/22/2023									Office below	er (give title v)			r (specify v)	
					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
7TH FLO	JOK													Line)	Form	filed by O				
(Street)																rm filed by More than One Reporting rson				
NEW YORK NY 10014						le '	10b5-	1(c)	Trar	ารลง	ction Indi	catio	n							
(City) (State) (Zip)						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - No	on-Deriva	ative \$	Sec	urities	Acc	quired	I, Dis	sposed of	or B	enefi	ciall	ly Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/			Execution Date,		3. Transaction Code (Instr. 8)					or 5. Am 4 and Secur Benef		int of	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership					
					(mona				v	Amount	(A) or (D)	Pric	e	Reported Transaction(s) (Instr. 3 and 4)		(., (,	(Instr. 4)		
Common Shares, no par value ("Common Shares") 03/22/20					023			J ⁽¹⁾		1,059,000	D	(1)	3,256,102			I	See footnote ⁽²		
		Tal	ble II								oosed of, o				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	Execution Date, if any		4. Transaction Code (Instr. 8)				e Exer ation D h/Day/		7. Title and Amount of Securities Underlying Derivative Security (In 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e (s l ally l g (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Benefic Owners (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date		Amour or Numbe of Shares	r						
		of Reporting Person* MENTS, LP					•	•	•			•				•		•	•	
	AVENUE	(First)	(N	liddle)																
7TH FLO	OOR																			
(Street) NEW YO	ORK	NY	10	0014																
(City)		(State)	(Z	ip)																
	nd Address o	of Reporting Person*																		
		(First) TMENTS, LP 7TH FLOOR	(N	liddle)																
(Street)	ORK	NY	10	0014		-														

Explanation of Responses:

(State)

(Zip)

(City)

^{1.} The RTW Funds (as defined below) exchanged 1,059,000 Common Shares for 1,059,000 pre-funded warrants pursuant to an Exchange Agreement, dated as of March 22, 2023, by and among the Issuer and the RTW Funds. Each pre-funded warrant represents the right to acquire one Common Share for an exercise price of \$0.001 per share. The pre-funded warrants are subject to a 9.99% beneficial ownership limitation and do not have an expiration date.

^{2.} This Form 4 is being filed by each of (i) RTW Investments, LP (the "Adviser") with respect to Common Shares held by certain investment funds managed by the Adviser (the "RTW Funds"), and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser.

RTW Investments, LP, By: /s/ 03/24/2023 Roderick Wong, Managing

<u>Partner</u>

Roderick Wong, M.D., By: /s/ Roderick Wong

03/24/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.